Table 5 Post-treatment haematologic adverse event (AE), treatment emergent AEs (TEAE), between Day 0 and Day 28
Condition | Treatment | Normal on admission | TEAE (n) | AE (n) | TEAE | AE | |||
|---|---|---|---|---|---|---|---|---|---|
n | % | n | N (total) | n | N (total) | % | % | ||
Neutropaenia | AS&AQ | 1350 | 95% | 144 | 1309 | 169 | 1323 | 11% | 13% |
Other artemisinin | 919 | 95% | 113 | 944 | 130 | 951 | 12% | 14% | |
Non-artemisinin | 602 | 92% | 63 | 536 | 80 | 538 | 12% | 15% | |
Anaemia | AS&AQ | 1141 | 59% | 343 | 1750 | 693 | 1751 | 20% | 40% |
Other artemisinin | 876 | 59% | 328 | 1462 | 650 | 1462 | 22% | 44% | |
Non-artemisinin | 590 | 68% | 29 | 717 | 82 | 718 | 4% | 11% | |
Thrombocytopaenia | AS&AQ | 343 | 73% | 28 | 463 | 39 | 463 | 6% | 8% |
Other artemisinin | 436 | 64% | 44 | 672 | 68 | 672 | 7% | 10% | |